Cargando…
Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007–2016
In response to the rising cost of cancer drugs, the National Comprehensive Cancer Network (NCCN) recently developed a value framework, known as “Evidence Blocks,” to grade the efficacy, safety, evidence quality, evidence consistency, and affordability of treatments included in its clinical guideline...
Autores principales: | Hwang, Thomas J, Kesselheim, Aaron S, Gyawali, Bishal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649801/ https://www.ncbi.nlm.nih.gov/pubmed/31360849 http://dx.doi.org/10.1093/jncics/pky016 |
Ejemplares similares
-
Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study
por: Gyawali, Bishal, et al.
Publicado: (2021) -
Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020) -
Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020
por: Jenei, Kristina, et al.
Publicado: (2023) -
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021) -
Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis
por: Gyawali, Bishal, et al.
Publicado: (2019)